Publications in collaboration with researchers from Pfizer (United States) (2)

2025

  1. Cost-effectiveness of apixaban in non-valvular atrial fibrillation (NVAF) based on effectiveness data from a Spanish study in clinical practice (real-world evidence)

    Expert review of cardiovascular therapy, Vol. 23, Núm. 1-2, pp. 45-51

2019

  1. ICUSI questionnaire validation. Quality of anticoagulation in patients with atrial fibrillation treated with vitamin K antagonists

    REC: CardioClinics, Vol. 54, Núm. 3, pp. 165-172